Society journal studies

The following studies, among others, will be published in Endocrine Society journals. Before print, they are edited and posted online in each journal’s
Early Release section. You can access the journals at www.endocrine.org.

Synthetic Glucocorticoid Reduces Human Placental System A Transport in Women Treated with Antenatal Therapy • Melanie C. Audette, John R. G. Challis, Rebecca L. Jones, Colin P. Sibley, and Stephen G. Matthews • We conclude that women who are at risk of preterm labor and receive sGC but deliver at term have significantly reduced placental system A amino acid transporter activity. Altered placental transporter function could impact on fetal growth and may contribute to developmental programming reported in both animal and clinical studies.

Racial Differences in Peripheral Insulin Sensitivity and Mitochondrial Capacity in the Absence of Obesity • James P. DeLany, John J. Dubé, Robert A. Standley, Giovanna Distefano, Bret H. Goodpaster, Maja Stefanovic-Racic, Paul M. Coen, and Frederico G.S. Toledo • When compared to CW, AAW have similar hepatic insulin sensitivity, but a muscle phenotype characterized by both lower insulin sensitivity and lower mitochondrial oxidative capacity. These observations occur in the absence of obesity and are not explained by physical activity. The only factor associated with lower insulin sensitivity in AAW was mitochondrial oxidative capacity. Because exercise training improves both mitochondrial capacity and insulin sensitivity, we suggest that it may be of particular benefit as a strategy for diabetes prevention in AAW.

Glucagon-Like Peptide (GCGL) Is a Novel Potential Thyrotropin (TSH)- releasing Factor (TRF) in Chickens: I) Evidence for Its Potent and Specifi c Action on Stimulating TSH mRNA Expression and Secretion in the Pituitary • Guian Huang, Chen He, Fengyan Meng, Juan Li, Jiannan Zhang, and Yajun Wang • The potent and specific action of GCGL on pituitary TSH expression and secretion, together with the partial accordance shown among the temporal expression profiles of GCGL in the hypothalamus and GCGLR and TSHβ in the pituitary, provides the first collective evidence that hypothalamic GCGL is most likely to be a novel TSH-releasing factor (TRF) functioning in chickens. The discovery of this novel potential TRF (GCGL) in a non-mammalian vertebrate species, i.e. chickens, would facilitate our comprehensive understanding of the hypothalamic control of pituitarythyroid axis across vertebrates.

Polybrominated Diphenyl Ether (DE-71) Interferes with Thyroid Hormone Action Independent of Effects on Circulating Levels of Thyroid Hormone • Ruby Bansal, Daniel Tighe, Amin Denai, Dorothea F. K. Rawn, Dean W. Gaertner, Doug L. Arnold, Mary E. Gilbert, and R. Thomas Zoeller • Tissue PBDEs were in the µ g/g lipid range, only slightly higher than observed in human fetal tissues. Thus, PBDE exposure reduces serum T4, but does not produce effects on tissues typical of low TH produced by PTU, demonstrating that the effects of chemical exposure on serum T4 levels may not always be a faithful proxy measure of chemical effects on the ability of thyroid hormone to regulate development and adult physiology.

Crosstalk between Nuclear MET and SOX9/β-Catenin Correlates with Castration Resistant Prostate Cancer • Yingqiu Xie, Wenfu Lu, Shenji Liu, Qing Yang, Brett S. Carver, Estelle Li, Yuzhuo Wang, Ladan Fazli, Martin Gleave, and Zhenbang Chen • Our findings reveal for the first time an essential role of nMET association with SOX9/β-Catenin in CRPC in vitro and in vivo, highlighting nuclear receptor tyrosine kinases (RTKs) activate cell reprogramming to drive recurrence and targeting nMET would be a new avenue to treat recurrent cancers.

Hey U(PS): Metabolic and Proteolytic Homeostasis Linked via AMPK and the Ubiquitin Proteasome System • Sarah M. Ronnebaum, Cam Patterson, and Jonathan C. Schisler • This review serves to identify the current understanding of the interplay between AMPK and the UPS and to promote further exploration of the relationship between these regulators of energy utilization and amino acid availability within the cell.

Inhibin at 90: From Discovery to Clinical Application, a Historical Review • Yogeshwar Makanji, Jie Zhu, Rama Mishra, Chris Holmquist, Winifred P.S. Wong, Neena B. Schwartz, Kelly E. Mayo, and Teresa K. Woodruff • In this review, we provide a comprehensive summary of our current understanding of the biological role of inhibin, its relationship with activin, its signaling mechanisms, and its potential value as a diagnostic marker for reproductive function and pregnancy-associated conditions.

Current Approaches and Recent Developments in the Management of Head and Neck Paragangliomas • David Taïeb, Alexandre Kaliski, Carsten C. Boedeker, Victoria Martucci, Tito Fojo, John R. Adler, Jr., and Karel Pacak • This review will also particularly emphasize current and emerging knowledge in genetics, imaging, and therapeutic options, as well as the health-related quality of life for patients with HNPGLs.

You may also like

  • Pharma Fridays – Oct. 18, 2024

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Olfactive Biosolutions Granted Patent to Repurpose Food Molecules for Treatment of Hypertension On October 15, Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted U.S. patent 12,102,611, Compositions And Methods For Treating Hypertension By Modulating…

  • Eureka 2023! Part IV: Top Endocrine Discoveries

    For the ninth year running, Endocrine News talks to editors from Endocrine Society publications to unearth the endocrine nuggets of 2023. Here, the editors of The Journal of Clinical Endocrinology & Metabolism and JCEM Case Reports weigh in on what they think qualify as the year’s biggest discoveries in endocrine science. Editor-in-Chief of JCEM, Paul…

Find more in